Clinical trial

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

NCT00080899

Study summary

ClinicalTrials.gov

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention fenretinide Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention laboratory biomarker analysis Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-06-01

PhasePHASE2

Conditions

Adenocarcinoma of the Prostateverified · MONDO: prostate adenocarcinoma

Recurrent Prostate Cancerunresolved

Interventions

fenretinideDRUG

laboratory biomarker analysisOTHER

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

Los AngelesCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00080899 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.